The use of real-time CGM is associated with a lower health cost of type 2 diabetes

Source / Statements

Disclosures: Norman has announced that he is a Dexcom employee. Please see the study for relevant financial statements from all other authors.


We were unable to process your request. Please try again later. If you continue to experience this problem, please contact [email protected]

The use of ongoing real-time monitoring of glucose is linked to a reduction in the cost of diabetes-related health care, according to a brief report published last year. Diabetes Technology and Therapy.

Gregory J. Norman

“This cohort of research consisted mostly of people with type 2 diabetes who used insulin.” Gregory J. Norman, Ph.D., Director of health economics and results research at Dexcom, told Healio. “We don’t know how the patients used real-time CGM from the data, but we can speculate that launching real-time CGM helped patients manage hypoglycemia and hyperglycemia, which could lead to costly hospitalizations.”

Using real-time CGM reduces the medical costs associated with diabetes
The use of real-time CGM is associated with a reduction in the medical costs associated with type 2 diabetes. Data Norman GJ, et al. Diabetes Technol Ther. 2022; doi: 10.1089 / dia.2021.0525.

Norman and colleagues conducted a retrospective analysis of the health care costs of people with type 2 diabetes. Commercial and Medicare Advantage claims with Part D beneficiaries were obtained from the Optum Research Database. Adults with at least one pharmacy claim for a Dexcom real-time CGM device between October 2017 and February 2019 who were enrolled in an ongoing health plan for 12 months before the start of the CGM and who remained enrolled for at least 6 months. The costs of using health care were determined from diagnostic and procedural codes for outpatient, ED visits, hospital care, and other medical care. Costs were considered to be related to diabetes if there was a diabetes diagnostic code during the visit. The main outcome was the difference in total diabetes-related medical costs before and after the onset of CGM.

The analysis included 571 adults with type 2 diabetes (mean age, 51.2 years; 46% women; 90% insulin-treated). The average cost of diabetes-related health care was $ 1,680 per person per month before using CGM and $ 1,256 per person per month, $ 424 less (95% CI; -816 to -31); P = .035). An overall decrease in diabetes-related medical costs before and after the onset of CGM (95% CI; -706 to -10); P = .044).

“It was a simple study that looked at the average monthly medical costs associated with diabetes as a result of hospital and outpatient care,” Norman said. “It was not surprising that the largest cost reduction was seen in hospital hospitals, as hospital stays tend to be the category of medical services with the highest cost for patients.”

Norman said more real-world studies and more randomized controlled trials are needed to further examine the clinical effects of real-time CGM in people with type 2 diabetes.

“Evidence is piling up for people who use insulin with type 2 diabetes, but more research is needed to determine if real-time CGM helps people earlier when they are taking non-insulin antidiabetic medications before starting insulin,” Norman said. “We still don’t know if real-time CGM can slow the progression of type 2 diabetes. I think real-time CGM can be a useful opinion tool for people with type 2 diabetes who don’t take insulin, and even those with pre-diabetes, activities, diets and sleep on their glycemic patterns. to understand how they affect them.

For more information:

Gregory J. Norman, Ph.D.[email protected]

Leave a Comment